Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…
Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2031. The treatment of metastatic colorectal cancer is…
Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable…
China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2021-2031…
The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…
China has a high disease burden of human immunodeficiency virus (HIV), but patients are well managed by different classes of antiretroviral therapies (ARTs), including single-tablet regimens (e.g…
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…